![](/assets/images/down.png)
![](/assets/images/up.png)
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
2023-11-02 | 2023-09 | -2.01 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
View our latest analysis for Moderna
It will come as no surprise to learn that the analysts have increased their price target for Moderna 5.0% to US$92.44 on the back of these upgrades. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Moderna analyst has a price target of US$134 per share,
-
Do whatever you need to do to be on the upswing tomorrow. Between the second round of funding and the only 3rd phase on the planet this is going to fly!
-
Between third phase starting and the new round of funding this is going to rocket tomorrow!
-
We rocket tomorrow.
Moderna gets further $472 million U.S. award for coronavirus vaccine development
July 26, 2020, 10:01 AM
Moderna Therapeutics seen during COVID-19 in Massachusetts
Moderna Therapeutics seen during COVID-19 in Massachusetts
(Reuters) - Moderna Inc said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate.
-
I’m buying more first thing !
-
-
Definitely BUY, first thing in the morning!
-
Get in early in the morning! This will break through 85 tomorrow!
-
Breaking News!
Moderna gets further $472 million U.S. award for coronavirus vaccine development
July 26, 2020, 10:01 AM
Moderna Therapeutics seen during COVID-19 in Massachusetts
Moderna Therapeutics seen during COVID-19 in Massachusetts
(Reuters) - Moderna Inc said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate.
-
The first Phase 3 coronavirus vaccine trial in the US is expected to begin next week. Here's how the vaccine works
By Andrea Kane, CNN
Updated 9:22 PM EDT, Fri July 24, 2020(CNN) Much of the world has pinned its hopes on a vaccine as a way out of the Covid-19 pandemic that has infected more than 15 million and killed more than 630,000 people globally.
The World Health Organization says there are 25 potential coronavirus vaccines in clinical trials internationally.
Here in the United States, the government has put its money behind several different vaccine candidates through Operation Warp Speed.
Even once a vaccine gets approved, big hurdles remain for distribution
Even once a vaccine gets approved, big hurdles remain for distributionOne of those vaccines is being developed by the Vaccine Research Center at the National Institutes of Health's National Institute of Allergy and Infectious Diseases, in partnership with the biotechnology company Moderna. The vaccine is expected to enter Phase 3 testing next week. This phase of the trial is expected to involve 30,000 volunteers and will test whether the vaccine protects people against the coronavirus.
-
Phase 3 , starting. I’m signing up!
Here's how to volunteer for a COVID-19 vaccine trial in Central Florida
Updated: 5:31 PM EDT Jul 22, 2020
DELAND, Fla. —
In the race to find a vaccine for the coronavirus, a DeLand lab has been selected as a site for a clinical research trial.Accel Clinical Research has been chosen by the Biotech company Moderna to oversee trials of a COVID-19 vaccine.
Advertisement
"We've been absolutely ecstatic about it," said Dr. Bruce Rankin, the lab’s medical director.Rankin said they have lots of experience doing clinical trials and successfully tested a vaccine for the swine flu 11 years ago.
For the coronavirus vaccine trial, they are looking for 2,500 participants between 18 and 85 years of age.
They would prefer people on the front lines of potential exposure such as health care, grocery store or even theme park workers.
He said the participants get the satisfaction of helping others.
"That's the big motivation, to come out and help promote medical science. A lot of things, you go down to your pharmacy, it's stuff we've worked on and shown it to be safe and effective," Rankin said.
Rankin said participants will be followed for 24 months and receive a stipend for their time, usually around $700 to $1,000.
Once they're accepted, they'll get the trial vaccine, which Rankin said he'll have in about a week.
"We need to make sure it’s safe, that's always the first thing. Is it something we can give to a millions of people and number two if we're giving it to them we got to make sure it's working and it's effective,” Rankin said.
Rankin said a vaccine could be ready for the masses by early next year.
People interested in participating can sign up here.
-
CNN: Moderna. The vaccine is expected to enter Phase 3 testing next week. This phase of the trial is expected to involve 30,000 volunteers and will test whether the vaccine protects people against the coronavirus.
The vaccine uses messenger RNA (mRNA), which are cells used to build proteins -- in this case, the proteins that are needed to build the coronavirus' spike protein, which the virus uses to attach itself to and infect human cells. Once the immune system learns to recognize this target -- thanks to the vaccine -- it can mount a response faster than if it encountered the virus for the first time due to an infection.
-
Moderna (MRNA)
MRNA’s primary focus is on creating and discovering messenger RNA therapies. MRNA has numerous mid-stage candidates to treat cardiovascular conditions, cancer, and more.
MRNA is also hard at work developing a coronavirus vaccine. The POWR Ratings show MRNA is ranked 6th of 338 Biotech stocks. MRNA aces every single POWR Ratings Component and has a Strong Buy rating. According to the top analysts, MRNA has a target price of $93.79, which is 9% above current prices. MRNA’s mRNA-1273 coronavirus vaccine candidate will enter a phase three study on July 27
-
Screaming buy at this price. Once phase 3 launches this will fly past 90.
-
Huge buying opportunity!
-
Once when Alnylam Pharmaceuticals tries to drug discovery using the company and RNAi technology, Arbutus complained of Alnylam, you may Alnylam has become settled out of court by paying $ 65 million to Abatasu.
As you can see from the amount of money in the past cases, the patent fee that Moderna might have to pay to Arbutus is "about booger".Should they pay for that?
-
The only 3rd Phase in the USA coming Monday! This will
! Get in now.
-
-
The only 3rd phase in the USA, starts Monday! Get in while you can.
-
-
Bavarian Nordic stock slides on Moderna mpox vaccine study (NASDAQ:MRNA)
news.google.com • -
Moderna updated COVID shot endorsed in EU (NASDAQ:MRNA)
news.google.com • -
Stephen Hoge Sells 318 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock
news.google.com • -
Moderna Stock (MRNA) Nears a Support Level, Is It a Buy?
news.google.com • -
Smart Money Is Betting Big In MRNA Options
news.google.com • -
(MRNA) Trading Advice
news.google.com • -
Moderna CFO sells over $12k in company stock
news.google.com •